| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Xiang Yang Zhang, Yun Long Tan, Dong Feng Zhou, Lian Yuan Cao, Gui Ying Wu, Qi Xu, Yan Shen, Colin N Haile, Therese A Kosten, Thomas R Koste. Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. Journal of psychiatric research. vol 41. issue 12. 2007-12-13. PMID:17095017. |
serum bdnf was measured in 124 schizophrenia patients chronically treated with clozapine (n=57), risperidone (n=23) or typical antipsychotics (n=44) and 50 healthy control subjects. |
2007-12-13 |
2023-08-12 |
human |
| Dayong Wang, Yukihiro Noda, Yuan Zhou, Atsumi Nitta, Hiroshi Furukawa, Toshitaka Nabeshim. Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission. Neuropharmacology. vol 53. issue 3. 2007-12-06. PMID:17632185. |
in the present study, we aimed to investigate the synergistic effect and mechanisms of a combined treatment with an atypical antipsychotic risperidone and galantamine, which is a nachr-allosteric modulator and a modest cholinesterase inhibitor, on the impairment of latent visuospatial learning and memory in mice resembling the cognitive impairment of schizophrenia. |
2007-12-06 |
2023-08-12 |
mouse |
| Dayong Wang, Yukihiro Noda, Yuan Zhou, Atsumi Nitta, Hiroshi Furukawa, Toshitaka Nabeshim. Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission. Neuropharmacology. vol 53. issue 3. 2007-12-06. PMID:17632185. |
the study indicates that galantamine and risperidone may have synergistic effect on the cognitive impairments in schizophrenia patients by synergistically promoting the nachr activation-dependent increase of dopamine d1 receptor-mediated neurotransmission. |
2007-12-06 |
2023-08-12 |
mouse |
| Sung-Wan Kim, Il-Seon Shin, Jae-Min Kim, Seung-Hyun Lee, Jeong-Hoon Lee, Bo-Hyun Yoon, Su-Jin Yang, Michael Y Hwang, Jin-Sang Yoo. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 7. 2007-12-06. PMID:17692448. |
amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. |
2007-12-06 |
2023-08-12 |
Not clear |
| Steven G Potkin, Miriam Cohen, John Panagide. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. The Journal of clinical psychiatry. vol 68. issue 10. 2007-11-19. PMID:17960962. |
this 6-week trial assessed the efficacy, tolerability, and safety of the investigational psychopharmacologic agent asenapine versus placebo and risperidone in patients with acute schizophrenia (dsm-iv criteria). |
2007-11-19 |
2023-08-12 |
Not clear |
| Robert A Lasser, Cynthia A Bossie, Young Zhu, Julie C Locklear, John M Kan. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 19. issue 2. 2007-10-31. PMID:17612845. |
long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. |
2007-10-31 |
2023-08-12 |
Not clear |
| Robert A Lasser, Cynthia A Bossie, Young Zhu, Julie C Locklear, John M Kan. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 19. issue 2. 2007-10-31. PMID:17612845. |
treatment with long-acting injectable risperidone was evaluated in young adults likely to be in the early stages of schizophrenia or schizoaffective disorder. |
2007-10-31 |
2023-08-12 |
Not clear |
| Jonathan K Wynn, Michael F Green, Joyce Sprock, Gregory A Light, Clifford Widmark, Christopher Reist, Stephen Erhart, Stephen R Marder, Jim Mintz, David L Braf. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophrenia research. vol 95. issue 1-3. 2007-10-24. PMID:17662577. |
effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. |
2007-10-24 |
2023-08-12 |
Not clear |
| Jonathan K Wynn, Michael F Green, Joyce Sprock, Gregory A Light, Clifford Widmark, Christopher Reist, Stephen Erhart, Stephen R Marder, Jim Mintz, David L Braf. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophrenia research. vol 95. issue 1-3. 2007-10-24. PMID:17662577. |
51 schizophrenia patients participated in a randomized, double-blind controlled trial on the effects of three commonly-prescribed antipsychotic medications (risperidone, olanzapine, or haloperidol) on ppi, startle habituation, and startle reactivity. |
2007-10-24 |
2023-08-12 |
Not clear |
| Jonathan K Wynn, Michael F Green, Joyce Sprock, Gregory A Light, Clifford Widmark, Christopher Reist, Stephen Erhart, Stephen R Marder, Jim Mintz, David L Braf. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophrenia research. vol 95. issue 1-3. 2007-10-24. PMID:17662577. |
these results support the conclusion that olanzapine effectively increased ppi in schizophrenia patients, but that risperidone and haloperidol had no such effects. |
2007-10-24 |
2023-08-12 |
Not clear |
| Hans-Jürgen Mölle. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs. vol 67. issue 11. 2007-10-23. PMID:17661527. |
long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. |
2007-10-23 |
2023-08-12 |
Not clear |
| Evaristo Akerele, Frances R Levi. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. The American journal on addictions. vol 16. issue 4. 2007-10-19. PMID:17661193. |
comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. |
2007-10-19 |
2023-08-12 |
Not clear |
| Evaristo Akerele, Frances R Levi. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. The American journal on addictions. vol 16. issue 4. 2007-10-19. PMID:17661193. |
a 14-week double blind study compared the efficacy of olanzapine to risperidone in reducing marijuana/cocaine craving and use in individuals with schizophrenia. |
2007-10-19 |
2023-08-12 |
Not clear |
| Veena Kumari, Elena Antonova, Mark A Geyer, Dominic Ffytche, Steven C R Williams, Tonmoy Sharm. A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics. The international journal of neuropsychopharmacology. vol 10. issue 4. 2007-10-18. PMID:16923324. |
thirty men with schizophrenia on stable doses of typical antipsychotics (n=10), risperidone (n=10) or olanzapine (n=10; 9 with usable fmri data) and 12 healthy men underwent psychophysiological testing and fmri during a tactile ppi paradigm. |
2007-10-18 |
2023-08-12 |
Not clear |
| Michael G Aman, Alexander A Vinks, Bart Remmerie, Erik Mannaert, Yaser Ramadan, Jessica Masty, Ronald L Lindsay, Krista Malon. Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clinical therapeutics. vol 29. issue 7. 2007-10-09. PMID:17825699. |
risperidone is a second-generation antipsychotic agent widely used in the treatment of schizophrenia and other psychotic disorders in adults. |
2007-10-09 |
2023-08-12 |
Not clear |
| Eva M Peñas-Lledó, Pedro Dorado, Macarena C Cáceres, Alfredo de la Rubia, Adrián Lleren. Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs. Clinical chemistry and laboratory medicine. vol 45. issue 7. 2007-10-05. PMID:17617023. |
it has been suggested that the a-1438g polymorphism alters promoter activity and expression of 5-ht2a receptors and might be responsible for the associations with schizophrenia and the efficacy of atypical antipsychotics such as risperidone. |
2007-10-05 |
2023-08-12 |
Not clear |
| Ya Mei Bai, Tzu Ting Chen, Jen-Yeu Chen, Wen-Ho Chang, Bojian Wu, Chih Hung Hung, Wen Kuo Li. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. The Journal of clinical psychiatry. vol 68. issue 8. 2007-09-24. PMID:17854246. |
previous studies showed clinical benefit of risperidone long-acting injection in the treatment of schizophrenia. |
2007-09-24 |
2023-08-12 |
Not clear |
| Eduard Parellad. Long-acting injectable risperidone in the treatment of schizophrenia in special patient populations. Psychopharmacology bulletin. vol 40. issue 2. 2007-09-14. PMID:17514188. |
long-acting injectable risperidone in the treatment of schizophrenia in special patient populations. |
2007-09-14 |
2023-08-12 |
Not clear |
| Divya Vohor. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia. Current opinion in investigational drugs (London, England : 2000). vol 8. issue 7. 2007-09-04. PMID:17659473. |
this review focuses on the comparative safety and efficacy profile of nine atypical antipsychotic drugs (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine), which may ultimately affect the therapeutic options available for patients with schizophrenia. |
2007-09-04 |
2023-08-12 |
Not clear |
| Stephan Ruhrmann, Werner Kissling, Otto-Michael Lesch, Max Schmauss, Ute Seemann, Michael Philip. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 5. 2007-08-28. PMID:17412473. |
efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. |
2007-08-28 |
2023-08-12 |
Not clear |